HCT 116 AXL KO Tet-inducible Cell Line
Invented at Queen's University Belfast
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 153206 |
| Antigen/Gene or Protein Targets | AXL |
| Parental Line | HCT 116 |
| Host | Human |
| Tissue | Colon |
| Disease Keywords | Colorectal cancer |
| Model | Knock-Out |
| Relevance | Receptor tyrosine kinase (RTK) screens identifed AXL as a protein which underpins the migratory/invasive phenotype in colorectal cancer (CRC) (Dunne et al., 2014). AXL was shown to be a poor prognostic marker and an important mediator of cell migration/invasiveness. The HCT 116 AXL KO Tet-inducible cell line enables further investigation into the target as a prognostic biomarker and therapeutic target. |
| Production Details | HCT 116 cells were transfected with pTRIPZ plasmid encoding Tet-inducible shRNA against AXL. Stably transfected cells were selected, maintained in mediumsupplemented with 0.5μg/mL puromycin and induced with 2μg/ml doxycycline. |
| Conditional | Yes |
| Conditional Description | Conditional knockdown of endogenous AXL expression upon treatment with Tetracycline |
| Research Area | Cancer, Cell Structure and Motility, Drug Discovery & Development |
| Growth/Phenotype Keywords | Invasion, migration |
| Recommended Growing Conditions | McCoy’s 5a Medium (GIBCO # 16600) + 10% FBS + 100 units/ml penicillin+ 100 μg/ml streptomycin |
| Cellosaurus ID | CVCL_HG04 |
References: 2 entries
Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546.
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Europe PMC ID: 24170546
Add a reference
References: 2 entries
Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546.
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Add a reference
